A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Status
Temporarily Closed
Cancer Type
Bladder Cancer
Kidney Cancer
Unknown Primary
Trial Phase
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT03397394
Protocol IDs
CO-338-085 (primary)
NCI-2018-01112
Study Sponsor
Clovis Oncology

Summary

The purpose of the ATLAS study is to determine how patients with locally advanced or metastatic urothelial carcinoma respond to treatment with rucaparib.